Watch On Demand
In “Indications and Limitations of Bilayer Wound Matrix-Based Lower Extremity Reconstruction: A Multidisciplinary Case-Control Study of 191 Wounds,” published in Plastic and Reconstructive Surgery, researchers sought to better understand the success rate of Integra® Bilayer Wound Matrix in a large institutional cohort.
In this webinar, Dr. John Fischer, Assistant Professor of Surgery and Director of Clinical Research at University of Pennsylvania Health System, presents the study data and shares case examples of degloving injury, necrotizing fasciitis and oncological reconstruction.
Watch the webinar to learn:
-
- Predictors of successful outcomes including social and demographic factors
- Cost implications of treating and managing complex lower extremity soft tissue wounds
- Metrics of quality outcomes such as length of stay, readmission, re-operation, operative time and amputation rate
“While these findings may seem intuitive, they really lend validity to this data,” says Dr. Fischer. “For the first time, we’re seeing real-world experience using Integra in practice in complex and challenging lower extremity wounds.”
Reference:
Shakir S, Messa CA 4th, Broach RB, Rhemtulla IA, Chatman B, D’Angelantonio A, Levin LS, Kovach SJ 3rd, Serletti JM, Fischer JP. Indications and Limitations of Bilayer Wound Matrix-Based Lower Extremity Reconstruction: A Multidisciplinary Case-Control Study of 191 Wounds. Plast Reconstr Surg. 2020 Mar;145(3):813-822.
INDICATIONS: Integra® Bilayer Wound Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds. The device is intended for one-time use.
CONTRAINDICATIONS: This device should not be used in patients with known sensitivity to bovine collagen or chondroitin materials. This device is not indicated for use in third-degree burns.
PRECAUTIONS:
- Do not resterilize. Discard all opened and unused portions of Integra Bilayer Wound Matrix.
- Device is sterile if the package is unopened and undamaged. Do not use if the package seal is broken.
- Discard device if mishandling has caused possible damage or contamination.
- Integra Bilayer Matrix Wound Dressing should not be applied until excessive exudate, bleeding, acute swelling and infection are controlled.
- Debridement or excision must be done thoroughly to remove any remaining necrotic tissue that may cause infection.
- The following complications are possible with the use of wound dressings. If any of the conditions occur, the device should be removed: infection, chronic inflammation (initial application of wound dressings may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain or swelling.
Please fill out the below form to access this premium content:
Watch On Demand
In “Indications and Limitations of Bilayer Wound Matrix-Based Lower Extremity Reconstruction: A Multidisciplinary Case-Control Study of 191 Wounds,” published in Plastic and Reconstructive Surgery, researchers sought to better understand the success rate of Integra® Bilayer Wound Matrix in a large institutional cohort.
In this webinar, Dr. John Fischer, Assistant Professor of Surgery and Director of Clinical Research at University of Pennsylvania Health System, presents the study data and shares case examples of degloving injury, necrotizing fasciitis and oncological reconstruction.
Watch the webinar to learn:
-
- Predictors of successful outcomes including social and demographic factors
- Cost implications of treating and managing complex lower extremity soft tissue wounds
- Metrics of quality outcomes such as length of stay, readmission, re-operation, operative time and amputation rate
“While these findings may seem intuitive, they really lend validity to this data,” says Dr. Fischer. “For the first time, we’re seeing real-world experience using Integra in practice in complex and challenging lower extremity wounds.”
Please fill out the below form to access this premium content:
INDICATIONS: Integra® Bilayer Wound Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds. The device is intended for one-time use.
CONTRAINDICATIONS: This device should not be used in patients with known sensitivity to bovine collagen or chondroitin materials. This device is not indicated for use in third-degree burns.
PRECAUTIONS:
- Do not resterilize. Discard all opened and unused portions of Integra Bilayer Wound Matrix.
- Device is sterile if the package is unopened and undamaged. Do not use if the package seal is broken.
- Discard device if mishandling has caused possible damage or contamination.
- Integra Bilayer Matrix Wound Dressing should not be applied until excessive exudate, bleeding, acute swelling and infection are controlled.
- Debridement or excision must be done thoroughly to remove any remaining necrotic tissue that may cause infection.
- The following complications are possible with the use of wound dressings. If any of the conditions occur, the device should be removed: infection, chronic inflammation (initial application of wound dressings may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain or swelling.